Financials
Financial year 2025
X - PHARMA from Verviers, company number BE0449256092, closed financial year 2025 with a result of € 9,962 after tax. For that financial year X - PHARMA recorded a gross margin of € 15,417 and equity of € 148,387. Compared with financial year 2024, the result moved from € 17,556 to € 9,962. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 6, 2026.
€ 148,387
▲ 7% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 9,962
▼ 43% vs 2024
Profit after tax over the fiscal year.
€ 93,051
▲ 16% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 86,387.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 951
▼ 27% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 812
▼ 76% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 15,738 | € 14,072 | € 15,485 | € 15,417 | |
| Profit after taxes | € 10,385 | € 9,173 | € 17,556 | € 9,962 | ▼ 43% |
| Equity | € 116,183 | € 120,869 | € 138,425 | € 148,387 | ▲ 7% |
| Total debts | € 1,353 | € 6,476 | € 4,739 | € 1,763 | ▼ 63% |
| Cash | € 52,899 | € 50,406 | € 80,204 | € 93,051 | ▲ 16% |
| Retained profit | € 54,183 | € 58,869 | € 76,425 | € 86,387 | ▲ 13% |
| Dividend | € 0 | € 4,488 | € 0 | € 0 | |
| Balance sheet total | € 117,536 | € 127,344 | € 143,164 | € 150,150 | ▲ 5% |
Key figures of X - PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to X - PHARMA?
What happened at X - PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Jean François CLASSEN stepped down as director. NBB
- MARIE-ODILE Renier stepped down as director. NBB
- Aurélie CLASSEN stepped down as director. NBB
- Alain CLASSEN stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 9,962 (▼ 43% vs 2024). Source: NBB ↗
- Jean François CLASSEN became a director. NBB
- MARIE-ODILE Renier became a director. NBB
- Aurélie CLASSEN became a director. NBB
In short
From € 10,385 profit in 2022 to € 9,962 profit in 2025.
Paid € 21,626 in corporate taxes since 2022.
Best year ever: 2024, with € 17,556 profit.
Paid out € 4,488 in dividends to the owners in total.
A new publication or filing at X - PHARMA? We notify you, reason included.
Follow X - PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
Jean François CLASSEN
Director
since 2023 · until 2029
since 2023 · until 2029
Aurélie CLASSEN
Director
since 2023 · until 2029
since 2023 · until 2029
Establishments
Establishment units
Physical locations of this company
Place de Petit-Rechain 21
4800 Verviers
Rue du Bief 16
4652 Herve
Active since 10 March 1993
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0449.256.092
- VAT number
- BE 0449.256.092
- Registered office
- Place de Petit-Rechain 21, 4800 Verviers
- Names & denominations
- X - PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 20 January 1993
- Peppol
- Active · Active since 15 Sept 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers